文献速递泌尿生殖与妇科肿瘤放疗消化道肿瘤放疗姑息放疗与转移瘤

盆腔放疗期间在线症状监测:eRAPID干预的随机预试验

Online Symptom Monitoring During Pelvic Radiation Therapy: Randomized Pilot Trial of the eRAPID Intervention.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-10-12

这项前瞻性两中心随机平行组预试验将167例接受根治性盆腔放疗的前列腺癌患者或接受放化疗的下消化道及妇科肿瘤患者随机分为常规护理组或eRAPID组。eRAPID组前列腺癌患者依从性良好,但妇科肿瘤放化疗患者依从性较低,未计划住院接触在两组间无差异。

要点

  • eRAPID系统成功整合入两个癌症中心的常规护理中。
  • 前列腺癌患者对eRAPID的依从性良好,而妇科肿瘤放化疗患者较低。
  • eRAPID组与常规护理组非计划住院接触均较低且无差异。

核心结论

  • eRAPID在两个癌症中心不同患者群体中成功添加至常规护理,可行性及可接受性得到确认,但前列腺癌患者依从性优,而妇科肿瘤放化疗患者较低。

研究设计与样本

  • 前瞻性两中心随机平行组预试验,纳入接受根治性盆腔放疗的前列腺癌患者或接受放化疗的下消化道及妇科肿瘤患者,随机分为常规护理组或eRAPID组。

主要发现

  • 228例患者中167例(73.2%)知情同意并随机分组(eRAPID组83例,常规护理组84例;前列腺癌放疗87例,放化疗80例),167例中150例完成24周研究。
  • 仅16例患者(9.6%)退出(eRAPID组10例,常规护理组6例)。
  • eRAPID组中前列腺癌放疗患者完成率高于放化疗患者(第1周93% vs 69%;第2周93% vs 68%;第12周69% vs 55%)。
  • 总体上超过50%的在线报告触发了针对较轻不良事件自我管理建议,非计划住院接触较低且eRAPID组与常规护理组间无差异。
  • 第6周时,放化疗-eRAPID组在基线校正后FACT-G、EORTC QLQ-C30和EQ5D视觉模拟量表的恶化程度小于常规护理组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation therapy (RT) and chemoRT for pelvic cancers increase survival but are associated with serious treatment-related symptoms. Electronic-patient self-Reporting of Adverse-events: Patient Information and aDvice (eRAPID) is a secure online system for patients to self-report symptoms, generating immediate advice for hospital contact or self-management. This pilot study aimed to establish feasibility and acceptability of the system. METHODS AND MATERIALS: In a prospective 2-center randomized parallel-group pilot study, patients undergoing radical pelvic RT for prostate cancer (prostateRT) or chemoRT for lower gastrointestinal and gynecological cancers were randomized to usual care (UC) or eRAPID (weekly online symptom reporting for 12, 18, and 24 weeks). Primary outcomes were recruitment/attrition, study completion, and patient adherence. Secondary outcomes were effect on hospital services and performance of patient outcome measures. Missing data, floor/ceiling effects, and mean change scores were examined for Functional Assessment of Cancer Therapy (FACT-G), European Organisation for Research and Treatment of Cancer, Quality of Life (EORTC QLQ C-30), self-efficacy, and EuroQol (EQ5D). RESULTS: From 228 patients approached, 167 (73.2%) were consented and randomized (83, eRAPID; 84, UC; 87, prostateRT; 80, chemoRT); 150 of 167 completed 24 study weeks. Only 16 patients (9.6%) withdrew (10, eRAPID; 6, UC). In the eRAPID arm, completion rates were higher in patients treated with prostateRT compared with chemoRT (week 1, 93% vs 69%; week 2, 93% vs 68%; week 12, 69% vs 55%). Overall, over 50% of online reports triggered self-management advice for milder adverse events. Unscheduled hospital contact was low, with no difference between eRAPID and UC. Return rates for outcome measures were excellent in prostateRT (97%-91%; 6-24 weeks) but lower in chemoRT (95%-55%; 6-24 weeks). Missing data were low (1%-4.1%), ceiling effects were evident in EQ5D-5L, self-efficacy-scale, and FACT-Physical Wellbeing. At 6 weeks, the chemoRT-eRAPID group showed less deterioration in FACT-G, EORTC QLQ-C30, and EQ5D-Visual Analogue Scale than UC, after baseline adjustment. CONCLUSIONS: eRAPID was successfully added to UC at 2 cancer centers in different patient populations. Acceptability and feasibility were confirmed with excellent adherence by prostate patients, but lower by those undergoing chemoRT for gynecological cancers.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Holch P, Absolom KL, Henry AM, et al. Online Symptom Monitoring During Pelvic Radiation Therapy: Randomized Pilot Trial of the eRAPID Intervention. Int J Radiat Oncol Biol Phys. 2022. PMID: 36241128. doi:10.1016/j.ijrobp.2022.09.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。